LiqBio biomedical company limited
Update：2026/08/06
Industries
Main Industry
Health Care
Main Product/Service
LiqBio Biomedical employs its flagship instrument CytoExplore to directly analyse and isolate rare cells from blood samples, thereby demonstrating the company’s technological strength in cancer detection, personalized medicine and new drug development.
Founded Year
2021
Unified Business No.
91096216
Status
Active
Number of Employees
0
Total Paid-in
Capital
146,250,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The company is committed to the research and development of high-end medical analysis instrument. Independent research and development technology in Taiwan and cross-field technicians integrating molecular biology, clinical, electromechanical, optoelectronics, and software to develop the CytoExplore apparatus, which has applied for a total of 22 patents. The CytoExplore apparatus can assist in solving the clinical needs of rare cell sorting, and its market application cancer detection, newborn screening, personalized medicine, new drug research and development, etc.
